Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15027

HTLV-1-associated myelopathy in Spain


Thumbnail

See/Open:
 HTLV_Mendoza_et_al_Jou_ClinViro_2023.pdf
471,74 kB
Adobe PDF
Title: HTLV-1-associated myelopathy in Spain
Authors : Mendoza, Carmen de
Pérez, Leire
Rando, Ariadna
Reina, Gabriel
Aguilera, Antonio
Benito, Rafael
Eirós, José María
Rodríguez-Avial, Itziar
Ortega, Diego
Pozuelo de Felipe, María José
Pena, María José
Soriano, Vicente
HTLV Spanish Network
Keywords: EpidemiologyHTLV-1MyelopathyPrenatal screeningSexually transmitted infectionsTesting
Publisher: Elsevier
Citation: de-Mendoza C, Pérez L, Rando A, Reina G, Aguilera A, Benito R, Eirós JM, Rodríguez-Avial I, Ortega D, Pozuelo MJ, Pena MJ, Soriano V; Spanish HTLV Network. HTLV-1-associated myelopathy in Spain. J Clin Virol. 2023 Dec;169:105619. doi: 10.1016/j.jcv.2023.105619. Epub 2023 Nov 21. PMID: 38000189.
Abstract: Background: HTLV-1 infection is a neglected disease. Over 10 million people are infected worldwide, with hot spots of high endemicity across all continents. Roughly 5% of HTLV-1 carriers develop HTLV-1-associated myelopathy (HAM), a progressive subacute neurological disabling disease. Methods: We report the main features of patients diagnosed with HAM up to date in Spain, a non-endemic country with a relatively high migrant flow from Latin America and Equatorial Africa, where HTLV-1 is endemic. Results: A total of 451 cases of HTLV-1 had been recorded in Spain until the end of year 2022. HAM had been diagnosed in 58 (12.9%). The current incidence is of 2-3 new cases per year. Women represent 76%. Mean age at diagnosis is 49 years-old. Nearly 60% are Latin Americans. Although sexual transmission is the most likely route of HTLV-1 acquisition, up to 6 individuals had been infected following solid organ transplantation. Rapid onset myelopathy developed in all but one of these transplant recipients from three HTLV-1-positive donors. HTLV-1 subtype 1a transcontinental was the only variant recognized in HAM patients. HTLV-1 proviral load was significantly greater in HAM patients than in asymptomatic HTLV-1 carriers (677 vs 104 HTLV-1 DNA copies/104 PBMC; p = 0.012). Symptom relief medications and physiotherapy have been the only treatment providing some benefit to HAM patients. Neither significant clinical nor virological efficacy was noticed using antiretrovirals in at least 9 HAM patients. Two thirds of HAM patients ended up in a wheelchair and with urinary/fecal sphincter incontinence. Conclusion: HAM is the most frequent clinical manifestation of HTLV-1 infection in Spain, a non-endemic country. Middle aged women migrants from Latin America are the most frequently affected. Two thirds end up in a wheelchair despite using antiretroviral therapy.
Description: Acceso al texto completo del artículo, disponible desde el sitio de la revista usando DOI: https://doi.org/10.1016/j.jcv.2023.105619
Este artículo está en acceso abierto siguiendo la política de la revista
URI: http://hdl.handle.net/10637/15027
ISSN: 1386-6532
Issue Date: 21-Nov-2023
Center : Universidad San Pablo-CEU
Appears in Collections:Facultad de Farmacia





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.